Abstract
Nitrative stress is a key component of the pathogenic process in Parkinson's disease (PD), but the relative roles of constitutive neuronal nitric oxide synthase (n-NOS) and inducible nitric oxide synthase (i-NOS) in glial cells remain unresolved. We have investigated the effects of a range of concentrations of the selective n-NOS inhibitor ARR17477, and the selective i-NOS inhibitor 1400W, on MPP(+)-induced cell death in foetal ventral mesencephalic (VM) dopaminergic cultures. MPP(+) induced a loss of TH-positive neurones accompanied by an increase in immunoreactivity for GFAP and OX-6 as markers of astrocytes and activated microglia, respectively, and induced i-NOS immunoreactivity. Unexpectedly, MPP(+) treatment did not induce 3-NT immunoreactivity in the cultures. ARR17477 and 1400W alone had no effect on the number of TH-positive cells or on the number of GFAP or OX-6 positive cells. ARR17477 did not prevent the MPP(+)-induced decrease in TH-positive neurones and had no effect on the increased number of GFAP- and OX-6-positive cells. By contrast, 1400W caused a concentration-dependent preservation of TH-positive neurones in the presence of MPP(+). It also significantly reduced the number of OX-6-immunoreactive cells and there was a small reduction in GFAP immunoreactivity. The results suggest a major role for i-NOS-mediated nitrative stress in microglia in MPP(+)-induced dopaminergic cell death and this may have important implications for developing neuroprotective strategies for PD.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amidines / pharmacology
-
Animals
-
Antibodies, Monoclonal / metabolism
-
Astrocytes / drug effects
-
Astrocytes / metabolism
-
Benzylamines / pharmacology
-
Cell Count
-
Cells, Cultured
-
Dopaminergic Neurons / drug effects*
-
Dopaminergic Neurons / enzymology
-
Dopaminergic Neurons / pathology
-
Dose-Response Relationship, Drug
-
Enzyme Inhibitors / pharmacology
-
Glial Fibrillary Acidic Protein / metabolism
-
Mesencephalon / drug effects
-
Mesencephalon / enzymology
-
Mesencephalon / pathology
-
Microglia / drug effects
-
Microglia / metabolism
-
Neuroprotective Agents / pharmacology*
-
Nitric Oxide Synthase Type I / antagonists & inhibitors*
-
Nitric Oxide Synthase Type I / metabolism
-
Nitric Oxide Synthase Type II / antagonists & inhibitors*
-
Nitric Oxide Synthase Type II / metabolism
-
Parkinson Disease / drug therapy
-
Parkinson Disease / enzymology
-
Picolines / toxicity*
-
Primary Cell Culture
-
Rats, Wistar
-
Thiophenes / pharmacology
-
Tyrosine / analogs & derivatives
-
Tyrosine / metabolism
-
Tyrosine 3-Monooxygenase / metabolism
Substances
-
Amidines
-
Antibodies, Monoclonal
-
Benzylamines
-
Enzyme Inhibitors
-
Glial Fibrillary Acidic Protein
-
N-(3-(aminomethyl)benzyl)acetamidine
-
N-(4-(2-((3-chlorophenylmethyl)amino)ethyl)phenyl)-2-thiophenecarboxamide
-
Neuroprotective Agents
-
OX-6 monoclonal antibody
-
Picolines
-
Thiophenes
-
3-nitrotyrosine
-
Tyrosine
-
Nitric Oxide Synthase Type I
-
Nitric Oxide Synthase Type II
-
Nos1 protein, rat
-
Nos2 protein, rat
-
Tyrosine 3-Monooxygenase
-
4-methylpyridine